Is Adverum Biotechnologies Stock a Good Investment?
Adverum Biotechnologies Investment Advice | ADVM |
- Examine Adverum Biotechnologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Adverum Biotechnologies' leadership team and their track record. Good management can help Adverum Biotechnologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Adverum Biotechnologies' business and its evolving consumer preferences.
- Compare Adverum Biotechnologies' performance and market position to its competitors. Analyze how Adverum Biotechnologies is positioned in terms of product offerings, innovation, and market share.
- Check if Adverum Biotechnologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Adverum Biotechnologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Adverum Biotechnologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Adverum Biotechnologies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Adverum Biotechnologies Stock
Researching Adverum Biotechnologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies recorded a loss per share of 5.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 21st of March 2024.
To determine if Adverum Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adverum Biotechnologies' research are outlined below:
| Adverum Biotechnologies had very high historical volatility over the last 90 days | |
| Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.6 M. Net Loss for the year was (117.17 M) with loss before overhead, payroll, taxes, and interest of (67.22 M). | |
| Adverum Biotechnologies currently holds about 235.84 M in cash with (90.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures | |
| Roughly 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Leonard Braden Michael of 25000 shares of Adverum Biotechnologies at 4.9356 subject to Rule 16b-3 |
Adverum Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adverum Biotechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adverum Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Adverum Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Adverum Biotechnologies' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-08 | 2017-09-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2020-05-28 | 2020-03-31 | -0.27 | -0.31 | -0.04 | 14 | ||
2019-05-08 | 2019-03-31 | -0.27 | -0.23 | 0.04 | 14 | ||
2019-03-06 | 2018-12-31 | -0.29 | -0.25 | 0.04 | 13 | ||
2018-11-08 | 2018-09-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2022-11-10 | 2022-09-30 | -0.34 | -0.4 | -0.06 | 17 | ||
2021-08-05 | 2021-06-30 | -0.39 | -0.45 | -0.06 | 15 | ||
2019-08-08 | 2019-06-30 | -0.29 | -0.23 | 0.06 | 20 |
Know Adverum Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adverum Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adverum Biotechnologies backward and forwards among themselves. Adverum Biotechnologies' institutional investor refers to the entity that pools money to purchase Adverum Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 311 K | Soleus Capital Management, L.p. | 2024-12-31 | 287.2 K | Regeneron Pharmaceuticals Inc | 2024-12-31 | 180.9 K | Nuveen Asset Management, Llc | 2024-12-31 | 172.4 K | Northern Trust Corp | 2024-12-31 | 152.6 K | Citadel Advisors Llc | 2024-12-31 | 149.1 K | Renaissance Technologies Corp | 2024-12-31 | 129.6 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 114.8 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 98 K | Bml Capital Management Llc | 2024-12-31 | 2.3 M | Tcg Crossover Management, Llc | 2024-12-31 | 1.8 M |
Adverum Biotechnologies' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 112.33 M.Market Cap |
|
Adverum Biotechnologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.96) | (0.91) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (1.61) | (1.53) |
Determining Adverum Biotechnologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Adverum Biotechnologies is a good buy. For example, gross profit margin measures Adverum Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adverum Biotechnologies' profitability and make more informed investment decisions.
Evaluate Adverum Biotechnologies' management efficiency
Adverum Biotechnologies has return on total asset (ROA) of (0.2983) % which means that it has lost $0.2983 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7626) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to drop to -0.64. In addition to that, Return On Capital Employed is likely to grow to -0.91. At this time, Adverum Biotechnologies' Intangible Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.45 | 11.14 | |
| Tangible Book Value Per Share | 7.45 | 11.11 | |
| Enterprise Value Over EBITDA | (0.58) | (0.61) | |
| Price Book Value Ratio | 0.82 | 0.86 | |
| Enterprise Value Multiple | (0.58) | (0.61) | |
| Price Fair Value | 0.82 | 0.86 | |
| Enterprise Value | 6.7 B | 6.4 B |
The leadership approach at Adverum Biotechnologies' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.134 |
Basic technical analysis of Adverum Stock
As of the 26th of March, Adverum Biotechnologies shows the Downside Deviation of 5.52, risk adjusted performance of 0.0139, and Mean Deviation of 3.87. Adverum Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Adverum Biotechnologies variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Adverum Biotechnologies is priced correctly, providing market reflects its regular price of 4.93 per share. Given that Adverum Biotechnologies has jensen alpha of 0.0167, we suggest you to validate Adverum Biotechnologies's prevailing market performance to make sure the company can sustain itself at a future point.Adverum Biotechnologies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adverum Biotechnologies' Outstanding Corporate Bonds
Adverum Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adverum Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adverum bonds can be classified according to their maturity, which is the date when Adverum Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US00775PAA57 Corp BondUS00775PAA57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAG06 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAE57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAB19 | View | |
| AER 385 29 OCT 41 Corp BondUS00774MAZ86 | View | |
| AER 33 30 JAN 32 Corp BondUS00774MAX39 | View | |
| AER 34 29 OCT 33 Corp BondUS00774MAY12 | View |
Understand Adverum Biotechnologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Adverum Biotechnologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0139 | |||
| Market Risk Adjusted Performance | 0.0202 | |||
| Mean Deviation | 3.87 | |||
| Semi Deviation | 5.16 | |||
| Downside Deviation | 5.52 | |||
| Coefficient Of Variation | 15036.01 | |||
| Standard Deviation | 4.97 | |||
| Variance | 24.67 | |||
| Information Ratio | 0.0041 | |||
| Jensen Alpha | 0.0167 | |||
| Total Risk Alpha | 0.0065 | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 0.0102 | |||
| Maximum Drawdown | 21.34 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 8.28 | |||
| Downside Variance | 30.46 | |||
| Semi Variance | 26.62 | |||
| Expected Short fall | (3.91) | |||
| Skewness | (0.19) | |||
| Kurtosis | (0.29) |
| Risk Adjusted Performance | 0.0139 | |||
| Market Risk Adjusted Performance | 0.0202 | |||
| Mean Deviation | 3.87 | |||
| Semi Deviation | 5.16 | |||
| Downside Deviation | 5.52 | |||
| Coefficient Of Variation | 15036.01 | |||
| Standard Deviation | 4.97 | |||
| Variance | 24.67 | |||
| Information Ratio | 0.0041 | |||
| Jensen Alpha | 0.0167 | |||
| Total Risk Alpha | 0.0065 | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 0.0102 | |||
| Maximum Drawdown | 21.34 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 8.28 | |||
| Downside Variance | 30.46 | |||
| Semi Variance | 26.62 | |||
| Expected Short fall | (3.91) | |||
| Skewness | (0.19) | |||
| Kurtosis | (0.29) |
Consider Adverum Biotechnologies' intraday indicators
Adverum Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adverum Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 12706.63 | |||
| Daily Balance Of Power | (0.84) | |||
| Rate Of Daily Change | 0.91 | |||
| Day Median Price | 5.14 | |||
| Day Typical Price | 5.07 | |||
| Price Action Indicator | (0.45) | |||
| Period Momentum Indicator | (0.47) | |||
| Relative Strength Index | 61.98 |
Adverum Biotechnologies Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 19th of December 2024 Other Reports | ViewVerify | |
| 17th of December 2024 Other Reports | ViewVerify |
Adverum Stock media impact
Far too much social signal, news, headlines, and media speculation about Adverum Biotechnologies that are available to investors today. That information is available publicly through Adverum media outlets and privately through word of mouth or via Adverum internal channels. However, regardless of the origin, that massive amount of Adverum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Adverum Biotechnologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Adverum Biotechnologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Adverum Biotechnologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Adverum Biotechnologies alpha.
Adverum Biotechnologies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Adverum Biotechnologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adverum Biotechnologies Corporate Management
| Jim Wang | Chief Officer | Profile | |
| Andrew Ramelmeier | Chief Officer | Profile | |
| Aneta Ferguson | General Counsel | Profile | |
| Romuald Corbau | Chief Officer | Profile | |
| Kalliopi MD | Senior Development | Profile | |
| Michael Steel | Senior Quality | Profile |
Already Invested in Adverum Biotechnologies?
The danger of trading Adverum Biotechnologies is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adverum Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adverum Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adverum Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share | Quarterly Revenue Growth (0.70) | Return On Assets | Return On Equity |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Adverum Biotechnologies' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.